SrasV1, PubMed, Curation, bibRecord, 000C55

[Development of peptidic MERS-CoV entry inhibitors].

Identifieur interne : 000C55 ( PubMed/Curation ); précédent : 000C54; suivant : 000C56

[Development of peptidic MERS-CoV entry inhibitors].

Auteurs : Shuai Xia ; Qian Wang ; Shu-Wen Liu ; Lu Lu ; Shi-Bo Jiang

Source :

Yao xue xue bao = Acta pharmaceutica Sinica [ 0513-4870 ] ; 2015.

RBID : pubmed:27169270

Descripteurs français

KwdFr :
- Antiviraux (pharmacologie), Conception de médicament, Coronavirus du syndrome respiratoire du Moyen-Orient (), Coronavirus du syndrome respiratoire du Moyen-Orient (physiologie), Dipeptidyl peptidase 4 (métabolisme), Glycoprotéine de spicule des coronavirus (métabolisme), Humains, Infections à coronavirus (traitement médicamenteux), Peptides (pharmacologie), Pénétration virale ().
MESH :
- métabolisme : Dipeptidyl peptidase 4, Glycoprotéine de spicule des coronavirus.
- pharmacologie : Antiviraux, Peptides.
- physiologie : Coronavirus du syndrome respiratoire du Moyen-Orient.
- traitement médicamenteux : Infections à coronavirus.
- Conception de médicament, Coronavirus du syndrome respiratoire du Moyen-Orient, Humains, Pénétration virale.

English descriptors

KwdEn :
- Antiviral Agents (pharmacology), Coronavirus Infections (drug therapy), Dipeptidyl Peptidase 4 (metabolism), Drug Design, Humans, Middle East Respiratory Syndrome Coronavirus (drug effects), Middle East Respiratory Syndrome Coronavirus (physiology), Peptides (pharmacology), Spike Glycoprotein, Coronavirus (metabolism), Virus Internalization (drug effects).
MESH :
- chemical , metabolism : Dipeptidyl Peptidase 4, Spike Glycoprotein, Coronavirus.
- chemical , pharmacology : Antiviral Agents, Peptides.
- drug effects : Middle East Respiratory Syndrome Coronavirus, Virus Internalization.
- drug therapy : Coronavirus Infections.
- physiology : Middle East Respiratory Syndrome Coronavirus.
- Drug Design, Humans.

Abstract

In 2012, a new SARS-like coronavirus emerged in the Middle East, namely the Middle East respiratory syndrome coronavirus (MERS-CoV). It has caused outbreaks with high mortality. During infection of target cell, MERS-CoV S protein S1 subunit binds to the cellular receptor (DPP4), and its S2 subunit HR1 and HR2 regions intact with each other to form a stable six-helix bundle to mediate the fusion between virus and target cell membranes. Hence, blocking the process of six-helix bundle formation can effectively inhibit MERS-CoV entry into the target cells. This review focuses on the recent advance in the development of peptidic entry inhibitors targeting the MERS-CoV S2 subunit.

PubMed: 27169270

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000C55

Links to Exploration step

pubmed:27169270

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Development of peptidic MERS-CoV entry inhibitors].</title>
<author><name sortKey="Xia, Shuai" sort="Xia, Shuai" uniqKey="Xia S" first="Shuai" last="Xia">Shuai Xia</name>
</author>
<author><name sortKey="Wang, Qian" sort="Wang, Qian" uniqKey="Wang Q" first="Qian" last="Wang">Qian Wang</name>
</author>
<author><name sortKey="Liu, Shu Wen" sort="Liu, Shu Wen" uniqKey="Liu S" first="Shu-Wen" last="Liu">Shu-Wen Liu</name>
</author>
<author><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name>
</author>
<author><name sortKey="Jiang, Shi Bo" sort="Jiang, Shi Bo" uniqKey="Jiang S" first="Shi-Bo" last="Jiang">Shi-Bo Jiang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:27169270</idno>
<idno type="pmid">27169270</idno>
<idno type="wicri:Area/PubMed/Corpus">000C55</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C55</idno>
<idno type="wicri:Area/PubMed/Curation">000C55</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C55</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Development of peptidic MERS-CoV entry inhibitors].</title>
<author><name sortKey="Xia, Shuai" sort="Xia, Shuai" uniqKey="Xia S" first="Shuai" last="Xia">Shuai Xia</name>
</author>
<author><name sortKey="Wang, Qian" sort="Wang, Qian" uniqKey="Wang Q" first="Qian" last="Wang">Qian Wang</name>
</author>
<author><name sortKey="Liu, Shu Wen" sort="Liu, Shu Wen" uniqKey="Liu S" first="Shu-Wen" last="Liu">Shu-Wen Liu</name>
</author>
<author><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name>
</author>
<author><name sortKey="Jiang, Shi Bo" sort="Jiang, Shi Bo" uniqKey="Jiang S" first="Shi-Bo" last="Jiang">Shi-Bo Jiang</name>
</author>
</analytic>
<series><title level="j">Yao xue xue bao = Acta pharmaceutica Sinica</title>
<idno type="ISSN">0513-4870</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (pharmacology)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Dipeptidyl Peptidase 4 (metabolism)</term>
<term>Drug Design</term>
<term>Humans</term>
<term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term>
<term>Middle East Respiratory Syndrome Coronavirus (physiology)</term>
<term>Peptides (pharmacology)</term>
<term>Spike Glycoprotein, Coronavirus (metabolism)</term>
<term>Virus Internalization (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (pharmacologie)</term>
<term>Conception de médicament</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (physiologie)</term>
<term>Dipeptidyl peptidase 4 (métabolisme)</term>
<term>Glycoprotéine de spicule des coronavirus (métabolisme)</term>
<term>Humains</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Peptides (pharmacologie)</term>
<term>Pénétration virale ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dipeptidyl Peptidase 4</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Peptides</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Virus Internalization</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Dipeptidyl peptidase 4</term>
<term>Glycoprotéine de spicule des coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Peptides</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Design</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Conception de médicament</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Humains</term>
<term>Pénétration virale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In 2012, a new SARS-like coronavirus emerged in the Middle East, namely the Middle East respiratory syndrome coronavirus (MERS-CoV). It has caused outbreaks with high mortality. During infection of target cell, MERS-CoV S protein S1 subunit binds to the cellular receptor (DPP4), and its S2 subunit HR1 and HR2 regions intact with each other to form a stable six-helix bundle to mediate the fusion between virus and target cell membranes. Hence, blocking the process of six-helix bundle formation can effectively inhibit MERS-CoV entry into the target cells. This review focuses on the recent advance in the development of peptidic entry inhibitors targeting the MERS-CoV S2 subunit.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27169270</PMID>
<DateCompleted><Year>2016</Year>
<Month>05</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0513-4870</ISSN>
<JournalIssue CitedMedium="Print"><Volume>50</Volume>
<Issue>12</Issue>
<PubDate><Year>2015</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Yao xue xue bao = Acta pharmaceutica Sinica</Title>
<ISOAbbreviation>Yao Xue Xue Bao</ISOAbbreviation>
</Journal>
<ArticleTitle>[Development of peptidic MERS-CoV entry inhibitors].</ArticleTitle>
<Pagination><MedlinePgn>1513-9</MedlinePgn>
</Pagination>
<Abstract><AbstractText>In 2012, a new SARS-like coronavirus emerged in the Middle East, namely the Middle East respiratory syndrome coronavirus (MERS-CoV). It has caused outbreaks with high mortality. During infection of target cell, MERS-CoV S protein S1 subunit binds to the cellular receptor (DPP4), and its S2 subunit HR1 and HR2 regions intact with each other to form a stable six-helix bundle to mediate the fusion between virus and target cell membranes. Hence, blocking the process of six-helix bundle formation can effectively inhibit MERS-CoV entry into the target cells. This review focuses on the recent advance in the development of peptidic entry inhibitors targeting the MERS-CoV S2 subunit.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xia</LastName>
<ForeName>Shuai</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Qian</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Shu-wen</ForeName>
<Initials>SW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lu</LastName>
<ForeName>Lu</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jiang</LastName>
<ForeName>Shi-bo</ForeName>
<Initials>SB</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>China</Country>
<MedlineTA>Yao Xue Xue Bao</MedlineTA>
<NlmUniqueID>21710340R</NlmUniqueID>
<ISSNLinking>0513-4870</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.14.5</RegistryNumber>
<NameOfSubstance UI="C042807">DPP4 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.14.5</RegistryNumber>
<NameOfSubstance UI="D018819">Dipeptidyl Peptidase 4</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018819" MajorTopicYN="N">Dipeptidyl Peptidase 4</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>5</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>5</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>5</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27169270</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C55 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000C55 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:27169270
   |texte=   [Development of peptidic MERS-CoV entry inhibitors].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:27169270" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

[Development of peptidic MERS-CoV entry inhibitors].

[Development of peptidic MERS-CoV entry inhibitors].

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki